teaser
Macmillan Cancer Support has published a new report praising the Cancer Drugs Fund for improving access to vital medicines for cancer patients.
↓Article continues below this sponsored advert↓
↑Advertisement↑
However, the report bemoans the lack of plans to ensure that cancer patients will continue to receive treatment once the Fund ends in 2014 and a new Value-Based Pricing System is introduced.
Mike Hobday, Senior Public Affairs Officer at Macmillan, who co-wrote the report, said:
